Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
Status:
Completed
Trial end date:
2017-05-18
Target enrollment:
Participant gender:
Summary
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of
ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with
ultra wide, 200° field angiography guided pan retinal photocoagulation in patients with
CSME-CI secondary to diabetes mellitus (Type 1 or 2).